Human alpha-galactosidase variants
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
1. A recombinant polynucleotide comprising a polynucleotide sequence encoding a recombinant alpha galactosidase A comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 158, wherein said amino acid sequence of said recombinant alpha galactosidase A comprises a glycine (G) at the position corresponding to residue 333 of SEQ ID NO: 158, and wherein said encoded recombinant alpha galactosidase A has alpha galactosidase A activity.
2. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A further comprises at least one additional substitution or substitution set at one or more of positions 24/202, 39/47, 39/47/217, 39/151, 39/282/337/398, 39/337/343/398, 39/393/398, 47/130, 47/151, 47/343/345/393, 48, 48/68, 48/68/217/391/393, 48/217, 48/345/393, 48/393, 59/143, 68, 68/345, 130, 130/158, 130/158/393, 130/345/393, 143/271, 143, 143/387, 151, 151/158/217/343/345/393, 151/206/282/337/343/345/398, 151/282/393, 151/345/393/398, 151/393, 158, 158/393, 202, 206, 206/217, 217, 217/337/345/398, 271, 282/393, 345, 337/343/345/398, 343, 343/345/393/398, 393, or 393/398, wherein the amino acid position(s) correspond to the amino acid sequence of SEQ ID NO: 158.
3. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A further comprises at least one substitution or substitution set 24S/202N, 39V/47D, 39V/47V/217K, 39V/151L, 39V/282N/337R/398A, 39V/337R/343G/398A, 39V/393V/398A, 47V/130E, 47V/151L, 47V/343D/345Q/393V, 48D, 48D/68E, 48D/217K, 48D/345Q/393V, 48D/393V, 59A/143S, 68E, 68E/345Q, 130E, 130E/158R, 130E/158R/393V, 130E/345Q/393V, 143S/271N, 143S, 143S/387N, 151L, 151L/158R/217K/343G/345Q/393V, 151L/206S/282N/337R/343D/345Q/398A, 151L/282N/393V, 151L/345Q/393V/398A, 151L/393V, 158R, 158R/393V, 202N, 206S, 206S/217K, 217K, 217K/337R/345Q/398A, 271N, 282N/393V, 337R/343G/345Q/398A, 343D, 343D/345Q/393V/398A, 393V, or 393V/398A, wherein the amino acid position(s) correspond to the amino acid sequence of SEQ ID NO: 158.
4. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 91% sequence identity to SEQ ID NO: 158.
5. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 95% sequence identity to SEQ ID NO: 158.
6. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 99% sequence identity to SEQ ID NO: 158.
7. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises the polypeptide sequence of SEQ ID NO: 240, 276, 288, or 292.
8. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A is
(a) more thermostable than the alpha galactosidase A of SEQ ID NO:2;
(b) more stable at pH 7 than the alpha galactosidase A of SEQ ID NO:2;
(c) more stable at pH 4 than the alpha galactosidase A of SEQ ID NO:2;
(d) more stable to exposure to serum than the alpha galactosidase A of SEQ ID NO:2;
(e) more lysosomally stable than the alpha galactosidase A of SEQ ID NO:2; or
(f) more readily taken up by cells than the alpha galactosidase A of SEQ ID NO: 2.
9. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A depletes more globotriaosylceramide from cells than the alpha galactosidase A of SEQ ID NO: 2.
10. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7; iii) increased tolerance to pH 4; iv) increased tolerance to serum; v) increased uptake into cells; vi) increased depletion of globotriaosylceramide from cells; vii) reduced immunogenicity; or a combination of any of i), ii), iii), iv), v), vi), and/or vii), as compared to a reference sequence of SEQ ID NO: 2.
11. The recombinant polynucleotide of claim 1 , wherein the polynucleotide sequence comprises SEQ ID NO: 239, 275, 287, or 291.
12. A host cell comprising the recombinant polynucleotide of claim 2 , wherein the host cell is an isolated bacterial cell, isolated yeast cell, isolated insect cell, isolated plant cell, or isolated mammalian cell.
13. The host cell of claim 12 , wherein the host cell is an isolated mammalian cell.
14. A host cell comprising the recombinant polynucleotide of claim 7 wherein the host cell is an isolated bacterial cell, isolated yeast cell, isolated insect cell, isolated plant cell, or isolated mammalian cell.
15. The host cell of claim 14 , wherein the host cell is an isolated mammalian cell.
16. A method of producing a recombinant alpha galactosidase A, comprising culturing said host cell of claim 12 , under conditions that said alpha galactosidase A encoded by said recombinant polynucleotide is produced.
17. The method of claim 16 , further comprising the step of recovering said alpha galactosidase A.
18. The method of claim 16 , further comprising the step of purifying said alpha galactosidase A.